Head-to-head evidence
3BNC117 vs UVAX-1107
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
3BNC117
Developed by Frontier Biotechnologies and partners
NCT03041012 · Phase 2 · completed
The trial randomly assigned 60 participants to four groups, including standard antiretroviral therapy alone and combinations containing 3BNC117, but treatment was not blinded. Its primary outcomes were virologic and reservoir measures rather than hard clinical outcomes, and the registry provides no results showing whether any primary comparison was met.
Next expected readout: December 2026 · NCT05300035 (registry estimate)
UVAX-1107
Developed by Uvax Bio
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 3BNC117's landscape · UVAX-1107's landscape